acute coronary syndrome

Does a Combination of Diabetes and Acute Coronary Syndrome Change the Revascularization Strategy?

The results of the FREEDOM (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multi-vessel Disease) trial have shown a lower rate of events in patients with diabetes and stable multivessel disease who were randomized to undergo myocardial revascularization surgery, compared to those who underwent angioplasty. Surgery even showed a mortality reduction that<a href="https://solaci.org/en/2018/01/22/does-a-combination-of-diabetes-and-acute-coronary-syndrome-change-the-revascularization-strategy/" title="Read more" >...</a>

ticagrelor-clopidogrel-compressor

Clopidogrel or Ticagrelor in Patients with Acute Coronary Syndrome Treated with New-Generation DES: CHANGE DAPT

Courtesy of Dr. Pablo Baglioni. This is a prospective observational study with a 1-year follow-up analyzing 2062 patients with acute coronary syndrome (ACS)&nbsp;who have been treated with coronary angioplasty using new-generation drug-eluting stents (DES). Patients were included between December 21, 2012 and August 25, 2015. On May, 2014, due to changes in international guidelines, clopidogrel<a href="https://solaci.org/en/2017/12/15/clopidogrel-or-ticagrelor-in-patients-with-acute-coronary-syndrome-treated-with-new-generation-des-change-dapt/" title="Read more" >...</a>

After 80: The octogenarian patients with acute coronary syndrome benefit from an aggressive strategy

This work published simultaneously in The New England Journal of Medicine showed that patients over eighty years may benefit from an aggressive and invasive treatment strategy that could be unnecessarily denied given age. The study was conducted in 16 centers in Norway and included 458 octogenarians patients admitted with acute coronary syndromes without ST-segment elevation<a href="https://solaci.org/en/2015/06/24/congress-item-8834/" title="Read more" >...</a>

ACCOAST: pretreatment with prasugrel in non-ST elevation acute coronary syndrome (NSTE-ACS) offers no benefit and increased bleeding

P2Y12 receptor inhibitors are effective in patients experiencing NSTE-ACS, however, the administration timing is not clear. This study evaluated the administration of prasugrel at the time of diagnosis of ACS or after performing coronary angiography when angioplasty was already decided. 4033 patients were included experiencing an NSTE-ACS troponin positive who had planned angiography between 2<a href="https://solaci.org/en/2015/06/24/congress-item-7945/" title="Read more" >...</a>

APPOSITION IV: self-expanding DES in acute coronary syndrome

This study was designed to compare the apposition and neointimal coverage of struts by optical coherence tomography (OCT) of the new self-expanding sirolimus &nbsp;eluting stent (STENTYS SES) at 4 and 9 months in patients with STE-ACS. 152 patients randomized to STENTYS SES (n = 90) versus zotarolimus-eluting balloon-expandable stent (n = 62) were included. The<a href="https://solaci.org/en/2015/06/24/congress-item-7875/" title="Read more" >...</a>

PRATO ACS: Rosuvastatin reduces the incidence of contrast nephropathy in patients with acute coronary syndrome who receive early invasive strategy

The aim of this study was to determine whether patients without ST-segment elevation acute coronary syndromes who were not taking statins previously, can receive high doses of rosuvastatin before coronary angiography or angioplasty and if this action could exert protection in renal function and reduce the incidence of contrast-induced nephropathy (CIN). This prospective study randomized<a href="https://solaci.org/en/2015/06/24/congress-item-6720/" title="Read more" >...</a>

AHA 2023

AHA 2023 | MINT: Liberal vs Restrictive Transfusion in Patients with Acute Coronary Syndrome

The aim of this study was to assess hard end points such as death or MI in patients with acute coronary syndrome (ACS) presenting hemoglobin levels lower than 10 mg/dl. It was a randomized multicenter double blind trial including 3506 participants. The study looked at different transfusion strategies, comparing restrictive strategy with 7-8 g/dl hemoglobin<a href="https://solaci.org/en/2023/11/16/aha-2023-mint-liberal-vs-restrictive-transfusion-in-patients-with-acute-coronary-syndrome/" title="Read more" >...</a>

TCT 2023 | ALIGN AR trial

TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome

This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one month (1,426 patients), followed by ticagrelor monotherapy for 12 months, while the other group received DAPT with ASA and ticagrelor during 12 months (1,424 patients). This study was<a href="https://solaci.org/en/2023/10/30/tct-2023-t-pass-trial-asa-and-ticagrelor-in-acute-coronary-syndrome/" title="Read more" >...</a>

terapia antitrombótica triple

MACT Study: Monotherapy with P2Y12 Inhibitor Associated with Colchicine after Acute Coronary Syndrome

Dual antiplatelet therapy (DAPT) is the current standard for preventing thrombotic events in high-risk patients with coronary artery disease, as well as in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). However, this approach increases the risk of bleeding. To reduce this risk, there have been studies that discontinued the use of<a href="https://solaci.org/en/2023/08/29/mact-study-monotherapy-with-p2y12-inhibitor-associated-with-colchicine-after-acute-coronary-syndrome/" title="Read more" >...</a>

enfermedad carotídea y coronaria severa

5 Year Evolution of PCI vs CABG in Large Randomized Studies on Acute and Chronic Coronary Syndrome

Left main lesions in acute coronary syndrome (ACS) represent a major risk and, at present, the best revascularization strategy is a matter of debate. Though many studies and registries have excluded this group of patients, there is data on the pros and cons of both percutaneous coronary intervention (PCI) and cardiac artery bypass graft (CABG).&nbsp;<a href="https://solaci.org/en/2023/06/16/5-year-evolution-of-pci-vs-cabg-in-large-randomized-studies-on-acute-and-chronic-coronary-syndrome/" title="Read more" >...</a>

Top